Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297128 | 0.86 | ACE2 (0.36) | ACE2BRD4P2RX7 | |
| SCHEMBL23798400 | 0.81 | P2RX7 (0.37) | ACE2P2RX7 | |
| SCHEMBL11318566 | 0.79 | BRD4 (0.35) | BRD4 | |
| SCHEMBL18999654 | 0.79 | CCR8 (0.33) | ACE2GABRA1GABRG2GABRB3BRD4 | |
| SCHEMBL27271494 | 0.75 | TSHR (0.34) | ACE2P2RX7 | |
| SCHEMBL12278113 | 0.74 | GPR55 (0.39) | P2RX7 | |
| SCHEMBL25846725 | 0.74 | ACE2 (0.33) | ACE2BRD4P2RX7 | |
| SCHEMBL12278257 | 0.73 | AHR (0.38) | BRD4P2RX7 | |
| SCHEMBL12278916 | 0.73 | TNF (0.36) | BRD4P2RX7 | |
| SCHEMBL31638839 | 0.73 | PARP1 (0.39) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2021-01-14 | — | — | US | disclosed |
| US-10683294-B2 | 5-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683294-B2 | 5-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | ACE2 638/4885GABRA1 1492/4885GABRG2 2118/4885 |
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | ACE2 638/4885GABRA1 1492/4885GABRG2 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.